GH Research (NASDAQ:GHRS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of GH Research (NASDAQ:GHRS) from a hold rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

A number of other research firms also recently commented on GHRS. New Street Research set a $65.00 price target on GH Research in a research note on Monday, August 10th. Zacks Research upgraded shares of GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Guggenheim boosted their target price on shares of GH Research from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, HC Wainwright restated a “buy” rating on shares of GH Research in a research report on Monday, August 10th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $45.00.

GH Research Price Performance

Shares of GHRS opened at $19.18 on Friday. The firm has a 50-day moving average of $24.76 and a 200-day moving average of $21.40. GH Research has a one year low of $12.04 and a one year high of $31.44. The company has a market cap of $1.32 billion, a PE ratio of -19.18 and a beta of 1.32.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06. Analysts expect that GH Research will post -1.20 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Troluce Capital Advisors LLC raised its stake in GH Research by 165.4% during the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after buying an additional 617,260 shares during the last quarter. Braidwell LP bought a new stake in GH Research during the second quarter valued at $5,571,000. Squarepoint Ops LLC bought a new stake in GH Research during the second quarter valued at $495,000. Renaissance Technologies LLC bought a new stake in GH Research during the first quarter valued at $290,000. Finally, Farther Finance Advisors LLC grew its holdings in GH Research by 9,720.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock worth $231,000 after acquiring an additional 9,720 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.